NCT02213289 2021-04-08
PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
University of Chicago
Phase 2 Completed
Clinical Trials
6 trialsNCT01285037 2018-02-20
A Study of LY2801653 in Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT01017731 2015-06-10
Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes
Eli Lilly and Company
Phase 2 Completed
NCT01253525 2014-06-18
Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas
Eli Lilly and Company
Phase 1 Completed
NCT00786383 2013-08-19
Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy
Eli Lilly and Company
Phase 1 Completed
NCT00793975 2013-08-19
Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy
Eli Lilly and Company
Phase 1 Completed